Multiple myeloma, one of the fastest-moving therapy areas, has just added another new treatment following FDA approval of Bristol-Myers Squibb's (BMS) and AbbVie's Empliciti (elotuzumab).
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.